Coinbase Billion Prediction Market Faces AI Lie Fallout
Coinbase’s plan to launch a $22 billion prediction market faces a public tests after an AI-generated alert wrongly cl...
What Is The Average Long Term Return Of Total Market Funds
This quick overview presents the typical long-term return profile of total market funds, helping frame diversified retirement and growth goals.
28,588 articles
Intel Stock Sinking Today: What Investors Should Know
A single trading session can spark headlines, but smarter investors look at the bigger picture. This guide breaks dow...
Top Cryptocurrencies for Beginners: A Practical Starter Guide
New to crypto? This beginner-friendly guide walks you through the top cryptocurrencies for beginners, how to evaluate...
Bitcoin Price News: Early Holders Sell $117M as Whales Buy the Dip
Two early Bitcoin holders liquidated $117 million in BTC on March 19, while big wallets doubled down on purchases in ...
This Retirement Rule Thumb Is Changing: Here’s Why Now
A long-standing rule for taking money in retirement is evolving. This article explains why this retirement rule thumb...
Prediction: Astera Labs Could Soar If Valuation Makes Sense
Astera Labs sits at a pivotal point in the data center supply chain. This article breaks down why the stock could ris...
Crypto Price Prediction Today: XRP, Solana, Shiba Inu Rally
A fresh wave of buying interest in XRP, Solana, and Shiba Inu hits the market as traders watch key resistance levels ...
Defy Altcoin Correction, Price: ICP and PI Rally as BTC Dips
Bitcoin slides below 70,000 as ICP and PI buck the broader market, delivering notable gains while Ethereum fights to ...
Will Explode Clarity Passes: XRP Hopes Rise on Senate Vote
A Senate committee greenlit the CLARITY Act in a 15-9 vote, sending the bill to the full chamber. Markets jumped as X...
Beaten-Down Dividend Aristocrats Scoop: 3 Names to Buy Now
Wall Street is rotating away from AI momentum toward steady, long-running dividend payers. The beaten-down dividend a...
This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status